InDex Pharmaceuticals Holding AB (publ) interim report January – June 2023
License agreement signed with Viatris Japan”We are thrilled to start our collaborative journey with Viatris Japan and work together to significantly improve the lives of patients suffering from ulcerative colitis,” said Jenny Sundqvist, CEO of InDex Pharmaceuticals. “Viatris Japan’s solid knowledge and presence in the gastroenterology therapy area will enable us to jointly maximize the potential of cobitolimod.” Period April – June 2023 · Net sales amounted to SEK 97.5 (0.0) million · Operating loss amounted to SEK 86.9 (–21.7) million · Result after tax amounted to SEK 90.0 (–